Katalin Keltai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6364916/publications.pdf Version: 2024-02-01



ΚΑΤΑΙΙΝ ΚΕΙΤΑΙ

| # | Article | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 219-229. | 6.3 | 651 |
| 2 | Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2021-2031. | 13.9 | 641 |
| 3 | Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2009-2020. | 13.9 | 526 |
| 4 | Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 205-218. | 6.3 | 426 |
| 5 | Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries. Circulation, 2014, 129, 1568-1576. | 1.6 | 324 |
| 6 | Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2032-2043. | 13.9 | 299 |
| 7 | Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology, 2018, 71, 2306-2315. | 1.2 | 296 |
| 8 | Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial. Canadian Journal of Cardiology, 2017, 33, 1027-1035. | 0.8 | 133 |
| 9 | Stroke Outcomes in the COMPASS Trial. Circulation, 2019, 139, 1134-1145. | 1.6 | 118 |
| 10 | Electrosynthesized molecularly imprinted polyscopoletin nanofilms for human serum albumin detection. Analytica Chimica Acta, 2017, 977, 1-9. | 2.6 | 73 |
| 11 | External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. European Heart Journal, 2018, 39, 750-757a. | 1.0 | 72 |
| 12 | Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery. JAMA Cardiology, 2021, 6, 1042. | 3.0 | 35 |
| 13 | Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. Canadian Journal of Cardiology, 2016, 32, 311-318. | 0.8 | 24 |
| 14 | Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. European Heart Journal, 2021, 42, 2995-3007. | 1.0 | 18 |
| 15 | Doxorubicin selectively suppresses mRNA expression and production of endothelin-1 in endothelial cells. Vascular Pharmacology, 2010, 53, 209-214. | 1.0 | 15 |
| 16 | Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. Stroke, 2020, 51, 2901-2909. | 1.0 | 15 |
| 17 | Changes of Endothelin-1 and Big Endothelin-1 Levels and Action Potential Duration during Myocardial Ischemia-reperfusion in Dogs with and without Ventricular Fibrillation. Journal of Cardiovascular Pharmacology, 2004, 44, S376-S379. | 0.8 | 13 |
| 18 | Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. International Journal of Stroke, 2019, 14, 270-281. | 2.9 | 11 |

Katalin Keltai

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Endothelins: a Possible Mechanism of Cytostatics-induced Cardiomyopathy. Leukemia and Lymphoma, 2004, 45, 351-355. | 0.6 | 7 |
| 20 | Endothelin-1 and Cardiac Function in Anthracycline-treated Patients: A 1-year Follow-up. Journal of Cardiovascular Pharmacology, 2004, 44, S372-S375. | 0.8 | 6 |
| 21 | Endothelin Gene Expression During Ischemia and Reperfusion. Journal of Cardiovascular Pharmacology, 2004, 44, S198-S201. | 0.8 | 6 |
| 22 | Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 786-795. | 1.4 | 6 |
| 23 | Effect of Incessant Ventricular Tachyarrhythmias on Serum Endothelin and Big-endothelin Levels. Journal of Cardiovascular Pharmacology, 2004, 44, S402-S406. | 0.8 | 5 |
| 24 | Effects of implantable cardioverter defibrillator implantation and shock application on serum endothelin-1 and big-endothelin levels. Clinical Science, 2002, 103, 233S-236S. | 1.8 | 3 |
| 25 | Spiegelmers as potential receptors for cTnI diagnostics. Analytical Methods, 2017, 9, 5091-5093. | 1.3 | 2 |